Monogram Orthopaedics, Inc.

NasdaqCM MGRM

Monogram Orthopaedics, Inc. EBT Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -4,310.41%

Monogram Orthopaedics, Inc. EBT Margin is -4,310.41% for the Trailing 12 Months (TTM) ending September 30, 2024. EBT Ratio (Earnings Before Tax Ratio) is the fraction of earnings before taxes to total revenue, indicating the company's profitability before the impact of tax expenses.
  • Monogram Orthopaedics, Inc. EBT Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was -772,887.50%, a -46,667.36% change year over year.
  • Monogram Orthopaedics, Inc. EBT Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was -1,652.62%.
Key data
Date EBT Margin Net Income Margin EBITDA Margin EBIT Margin
Market news
NasdaqCM: MGRM

Monogram Orthopaedics, Inc.

CEO Mr. Benjamin Sexson C.F.A.
IPO Date May 18, 2023
Location United States
Headquarters 3913 Todd Lane
Employees 28
Sector Technology
Industries
Robotics Biotechnology
Description

Monogram Orthopaedics, Inc. focuses on developing a product solution architecture to enable mass personalized optimization of orthopedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures. Its robot prototype executes optimized paths for high-precision insertion of optimized implants in synthetic bone specimens. The company was formerly known as Monogram Arthroplasty Inc. and changed its name to Monogram Orthopaedics, Inc. in March 2017. The company was incorporated in 2016 and is headquartered in Austin, Texas.

StockViz Staff

January 15, 2025

Any question? Send us an email